tetano
Editor, Senior Moderator
Sci Rep
. 2021 Jul 27;11(1):15223.
doi: 10.1038/s41598-021-94624-4.
Lower peripheral blood Toll-like receptor 3 expression is associated with an unfavorable outcome in severe COVID-19 patients
Maria Clara Saad Menezes[SUP] 1 [/SUP], Alicia Dudy Müller Veiga[SUP] 2 [/SUP], Thais Martins de Lima[SUP] 2 [/SUP], Suely Kunimi Kubo Ariga[SUP] 2 [/SUP], Hermes Vieira Barbeiro[SUP] 2 [/SUP], Claudia de Lucena Moreira[SUP] 2 [/SUP], Agnes Araujo Sardinha Pinto[SUP] 2 [/SUP], Rodrigo Antonio Brandao[SUP] 2 [/SUP], Julio Flavio Marchini[SUP] 2 [/SUP], Julio Cesar Alencar[SUP] 2 [/SUP], Lucas Oliveira Marino[SUP] 2 [/SUP], Luz Marina Gomez[SUP] 2 [/SUP], Niels Olsen Saraiva Camara[SUP] 3 [/SUP], Heraldo P Souza[SUP] 2 [/SUP]
Affiliations
Abstract
The role of innate immunity in COVID-19 is not completely understood. Therefore, this study explored the impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection on the expression of Pattern Recognition Receptors (PRRs) in peripheral blood cells and their correlated cytokines. Seventy-nine patients with severe COVID-19 on admission, according to World Health Organization (WHO) classification, were divided into two groups: patients who needed mechanical ventilation and/or deceased (SEVERE, n = 50) and patients who used supplementary oxygen but not mechanical ventilation and survived (MILD, n = 29); a control group (CONTROL, n = 17) was also enrolled. In the peripheral blood, gene expression (mRNA) of Toll-like receptors (TLRs) 3, 4, 7, 8, and 9, retinoic-acid inducible gene I (RIGI), NOD-like receptor family pyrin domain containing 3 (NLRP3), interferon alpha (IFN-α), interferon beta (IFN-β), interferon gamma (IFN-γ), interferon lambda (IFN-λ), pro-interleukin(IL)-1β (pro-IL-1β), and IL-18 was determined on admission, between 5-9 days, and between 10-15 days. Circulating cytokines in plasma were also measured. When compared to the COVID-19 MILD group, the COVID-19 SEVERE group had lower expression of TLR3 and overexpression of TLR4.
. 2021 Jul 27;11(1):15223.
doi: 10.1038/s41598-021-94624-4.
Lower peripheral blood Toll-like receptor 3 expression is associated with an unfavorable outcome in severe COVID-19 patients
Maria Clara Saad Menezes[SUP] 1 [/SUP], Alicia Dudy Müller Veiga[SUP] 2 [/SUP], Thais Martins de Lima[SUP] 2 [/SUP], Suely Kunimi Kubo Ariga[SUP] 2 [/SUP], Hermes Vieira Barbeiro[SUP] 2 [/SUP], Claudia de Lucena Moreira[SUP] 2 [/SUP], Agnes Araujo Sardinha Pinto[SUP] 2 [/SUP], Rodrigo Antonio Brandao[SUP] 2 [/SUP], Julio Flavio Marchini[SUP] 2 [/SUP], Julio Cesar Alencar[SUP] 2 [/SUP], Lucas Oliveira Marino[SUP] 2 [/SUP], Luz Marina Gomez[SUP] 2 [/SUP], Niels Olsen Saraiva Camara[SUP] 3 [/SUP], Heraldo P Souza[SUP] 2 [/SUP]
Affiliations
- PMID: 34315957
- DOI: 10.1038/s41598-021-94624-4
Abstract
The role of innate immunity in COVID-19 is not completely understood. Therefore, this study explored the impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection on the expression of Pattern Recognition Receptors (PRRs) in peripheral blood cells and their correlated cytokines. Seventy-nine patients with severe COVID-19 on admission, according to World Health Organization (WHO) classification, were divided into two groups: patients who needed mechanical ventilation and/or deceased (SEVERE, n = 50) and patients who used supplementary oxygen but not mechanical ventilation and survived (MILD, n = 29); a control group (CONTROL, n = 17) was also enrolled. In the peripheral blood, gene expression (mRNA) of Toll-like receptors (TLRs) 3, 4, 7, 8, and 9, retinoic-acid inducible gene I (RIGI), NOD-like receptor family pyrin domain containing 3 (NLRP3), interferon alpha (IFN-α), interferon beta (IFN-β), interferon gamma (IFN-γ), interferon lambda (IFN-λ), pro-interleukin(IL)-1β (pro-IL-1β), and IL-18 was determined on admission, between 5-9 days, and between 10-15 days. Circulating cytokines in plasma were also measured. When compared to the COVID-19 MILD group, the COVID-19 SEVERE group had lower expression of TLR3 and overexpression of TLR4.